Reason for request
Inclusion of the list of medicines reimbursed by National Insurance and approved for use by hospitals. .
Clinical Benefit
| Substantial |
The actual benefit of these drugs is substantial. |
Clinical Added Value
| minor |
INOVELON offers a minor (level IV) improvement in actual benefit in the therapeutic management of patients aged 4 and over with Lennox-Gastaut syndrome that is resistant to first-line treatments. |
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
nkDaTaUyrvdrAHnh
